These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26845943)

  • 21. Novel hepatitis C drugs in current trials.
    Kronenberger B; Welsch C; Forestier N; Zeuzem S
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of interferon resistance in hepatitis C.
    Gretch D
    Lancet; 2001 Nov; 358(9294):1662-4. PubMed ID: 11728538
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment for hepatitis C before and after liver transplantation].
    Ueda Y; Marusawa H
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():306-10. PubMed ID: 26845950
    [No Abstract]   [Full Text] [Related]  

  • 24. Hepatitis C treatment gets into a new gear.
    Khokhar N
    J Coll Physicians Surg Pak; 2014 Dec; 24(12):879-81. PubMed ID: 25523720
    [No Abstract]   [Full Text] [Related]  

  • 25. Hepatitis C virus infection in end stage renal disease and after kidney transplant.
    Rodriguez-Castro KI; Morisco F; Rigotti P; Rugge M; Burra P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):340-2. PubMed ID: 25267966
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment of hepatitis C. Different modalities based on viral genotype].
    Pariente A
    Rev Prat; 2003 Jun; 53(11):1175-6. PubMed ID: 15185639
    [No Abstract]   [Full Text] [Related]  

  • 27. [Hepatitis C virus genotype 4: epidemiology and treatment].
    Castera L; Morice Y; Grando V; Bon C; Dény P; Roulot D
    Gastroenterol Clin Biol; 2003 Jun; 27(6-7):596-604. PubMed ID: 12910223
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment efficacy and safety in elderly genotype 1b chronic hepatitis C patients with high viral load].
    Nishikawa H
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():209-13. PubMed ID: 26845932
    [No Abstract]   [Full Text] [Related]  

  • 29. Advances in and the future of treatments for hepatitis C.
    Cheng R; Tu T; Shackel N; McCaughan GW
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):633-47. PubMed ID: 24846594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C.
    Rivero-Juarez A; Camacho A; Rivero A
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1157-65. PubMed ID: 26004270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [How to treat non-responders to antiviral bitherapy for hepatitis C?].
    Guyader D
    Gastroenterol Clin Biol; 2007 Mar; 31(3):317-24. PubMed ID: 17396096
    [No Abstract]   [Full Text] [Related]  

  • 32. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.
    Kwong AD; Najera I; Bechtel J; Bowden S; Fitzgibbon J; Harrington P; Kempf D; Kieffer TL; Koletzki D; Kukolj G; Lim S; Pilot-Matias T; Lin K; Mani N; Mo H; O'Rear J; Otto M; Parkin N; Pawlotsky JM; Petropoulos C; Picchio G; Ralston R; Reeves JD; Schooley RT; Seiwert S; Standring D; Stuyver L; Sullivan J; Miller V; ; ; ;
    Gastroenterology; 2011 Mar; 140(3):755-60. PubMed ID: 21255574
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug-resistant viral hepatitis.
    Wright M; Main J; Thomas HC
    J Infect; 2000 Jul; 41(1):1-4. PubMed ID: 10942634
    [No Abstract]   [Full Text] [Related]  

  • 35. Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3.
    Patel H; Heathcote EJ
    Gut; 2011 Jun; 60(6):879. PubMed ID: 20966029
    [No Abstract]   [Full Text] [Related]  

  • 36. [Development status of DAA against hepatitis C].
    Kato N; Nakagawa R; Goto K; Muroyama R; Matsubara Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():262-8. PubMed ID: 26845942
    [No Abstract]   [Full Text] [Related]  

  • 37. Excitement grows for potential revolution in hepatitis C virus treatment.
    Opar A
    Nat Rev Drug Discov; 2010 Jul; 9(7):501-3. PubMed ID: 20592732
    [No Abstract]   [Full Text] [Related]  

  • 38. The efficacy of new antiviral regimens for hepatitis C infection: Evidence from a systematic review.
    Younossi ZM
    Hepatology; 2018 Mar; 67(3):1160-1162. PubMed ID: 29023922
    [No Abstract]   [Full Text] [Related]  

  • 39. Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.
    Welsch C
    Drug Discov Today Technol; 2014 Mar; 11():19-25. PubMed ID: 24847649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Argentine consensus on hepatitis C 2013].
    Reggiardo MV; Tanno F; Mendizabal M; Galdame O
    Acta Gastroenterol Latinoam; 2014 Jun; 44(2):154-73. PubMed ID: 25199310
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.